Lifetime treatment costs of β-thalassaemia major

Abstract

Beta-thalassaemia major is a serious genetic disorder, which results in a considerable increase in both acute and chronic morbidity, and mortality. Although beta-thalassaemia major is a rare disease affecting approximately 600 people in the UK, treatment is intensive and predictions of the costs incurred may aid health care planning. In this report, the cost to the health service of providing treatment services for beta-thalassaemia major patients, over the course of a lifetime, is calculated in order to assist resource allocation decisions. A cost model was developed, incorporating data from disparate sources. The undiscounted lifetime cost of treating a beta-thalassaemia major patient was estimated to be pound 803,002, although when the costs were discounted at a rate of 6%, the lifetime cost was reduced to pound 219,068. Within sensitivity analyses, the discounted cost ranged from approximately pound 188,000 to pound 226,000. This report may act as a guide to those involved in the planning of health care provision with regard to the resources required to treat beta-thalassaemia major patients. Such information may also be incorporated into the decision-making process for the provision of antenatal screening programmes for beta-thalassaemia major.

Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

“…Among the four published studies we identified, [21][22][23][24] only one 22 reported the mean annual ICT per-patient cost, which was estimated to range from $12,719 to $24,845 (USD 1998), but only the costs associated with DFO and home healthcare services were included. In another of these studies, 24 the lifetime cost of DFO was estimated to be about $63,000 (USD 1996).…”

“…Only four studies were identified that contained data related to the costs of infused ICT. [21][22][23][24] On the basis of the literature, a single composite list of cost variables (such as drug, equipment, monitoring toxic effects, and psychotherapist) was created to serve as the basis for the health economics component of the case report form. Frequency of use and unit cost data for each of these variables were identified from the literature, this study, administrative databases, and medical supply catalogues.…”

Patient Engagement: Four Case Studies That Highlight The Potential For Improved Health Outcomes And Reduced Costs

“…One study estimated the undiscounted lifetime cost of treating the disease at £803,002 ($1,332,980). 19 The experience in the UAE demonstrates the value of engaging college students to promote genetic screening. Being educated in the scienc-es, the student ambassadors were quick to grasp the potential value of screening and effective at delivering the message to other students.…”

Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan

“…In the developing world, the vast majority of affected children die before the age of 20 years because of the unavailability of most forms of effective treatment. 2,3 The lifetime cost of treating a patient with thalassemia major is estimated to be d80 000 (4US$ 110 000) in the United Kingdom 4,5 and US$ 284 154 in Israel. 6 Recent data from the Taiwan Thalassemia Association indicate that more than 400 patients have b-thalassemia major or other transfusion-dependent thalassemias in Taiwan, and their treatment costs account for a considerable percentage of the Taiwan's National Health Insurance expenditure.…”